In April 2020, as the world focused on COVID-19, eight people in California were hospitalized with a different kind of lung crisis. They had e-cigarette, or vaping, product use-associated lung injury (EVALI)—a severe illness that damages the lungs and was first widely recognized in 2019. This field report from the California Department of Public Health shows these cases were still happening during the pandemic's chaotic start. The report simply tells us these eight people were hospitalized and that doctors linked their injuries to vaping. We don't know what happened to them afterward, how sick they were, or what specific products they used. Because this is just a case series—a report of what happened to a specific group—it can't tell us if vaping caused the injuries for sure, only that there was an association. It also can't tell us if this was happening more or less often than before, since there's no comparison group. It's a reminder that a known danger was still present, even when our attention was elsewhere.
Eight California EVALI cases reported during early COVID-19 pandemic in field reportWhat happened to eight California vapers hospitalized during the early pandemic?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
A field report case series from California described 8 patients hospitalized with e-cigarette, or vaping, product use-associated lung injury (EVALI) reported to the California Department of Public Health in April 2020, during the early COVID-19 pandemic. The study reported an association between e-cigarette or vaping product use and lung injury. No comparator group was included in the analysis.
The main finding was the reporting of 8 EVALI cases. No specific outcome measures, effect sizes, or statistical comparisons were reported. Safety and tolerability data were not reported.
Key limitations include the case series design without a control group, which prevents assessment of causality or comparative risk. The small sample size from a single state limits generalizability. Funding sources and conflicts of interest were not reported.
For practice, this report serves as a surveillance update confirming EVALI cases occurred during the early pandemic period. It reinforces the need for clinicians to maintain awareness of EVALI and inquire about vaping history in patients presenting with respiratory symptoms, while recognizing this evidence is descriptive rather than causative.